Biohaven launches trial of Nurtec for sinusitis
Biohaven has launched enrollment for a Phase 2/3 clinical trial of a 75 mg dose of Nurtec ODT (rimegepant) in patients with chronic rhinosinusitis, or long-term...
Home >
Access the latest news, business developments, company updates, industry trends, events and more.
Biohaven has launched enrollment for a Phase 2/3 clinical trial of a 75 mg dose of Nurtec ODT (rimegepant) in patients with chronic rhinosinusitis, or long-term...
The FDA has approved Jardiance® (empagliflozin) 10 mg to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure, Boehringer Ingelheim and...
View this email in your browser Weekly Roundup – March 3, 2022 In honor of Women’s History Month, BioCT in celebrating Women in Bio and the work they...
Biohaven has launched enrollment for a Phase 2/3 clinical trial of a 75 mg dose of Nurtec ODT (rimegepant) in patients with chronic rhinosinusitis, or long-term...
Quantum-Si, the Guilford-based life sciences company, reports that the company’s founder, Jonathan Rothberg, who also chairs its board of directors, is now interim CEO. Rothberg succeeds...
Based in the downtown Hartford community, the UConn Health Disparities Institute was launched in 2017 as part of Bioscience Connecticut. It enhances research to improve the delivery of...
Patients with a rare and aggressive form of prostate cancer showed improvement after treatment with a drug from BioXcel Therapeutics, the company reports. A combination of...
Biohaven’s oral migraine drug performed well in a pivotal clinical trial in China and South Korea, the company reports. Rimegepant, the New Haven biotech’s calcitonin...
View this email in your browser Weekly Roundup – February 23, 2022 Alexion, a BioCT member, is a global biopharmaceutical company focused on developing and delivering life-transforming therapies...
Dr. Eric Winer’s plans for the Yale Cancer Center and Smilow Cancer Hospital include strengthening the ties between scientists and clinicians. Winer recently started his new job as the...